Roche received FDA clearance for its Solo insulin patch pump, but is expected to face significant barriers to entry in the highly competitive US insulin pump market.

The complaint says that EOFlow developed its EOPatch insulin delivery system with the help of former Insulet employees and Insulet’s contract manufacturer. Medtronic announced plans to acquire EOFlow in May, and US FDA clearance is on the horizon.

Abbott announced today it plans to integrate its FDA-cleared modified CGMs with insulin pump makers, including Tandem and Insulet, likely later this year.

Insulet will acquire insulin pump patents from Bigfoot Biomedical for $25m, which Bigfoot will use to expand its Unity diabetes management system. Insulet also announced the acquisition of automated insulin delivery assets held by Automated Glucose Control.